Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update

INSMED Inc (INSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update —Total Company Revenues of $524.4 Million for the Third Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $400.1 Million for the Third Quarter of 2026, Reflecting 29% Growth Over t

Event · Earnings
Also in this documentGuidance · raise · $1.35B–$1.4B

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 29, 2026, 11:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 11:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$INSM
Bullish
high confidence
Mentioned
$INSM
Relevance
9/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$INSMBullishHigh
01

Why it matters

The company raised guidance for both BRINSUPRI and ARIKAYCE, received Japan approval and launched BRINSUPRI tablets, and the FDA accepted ARIKAYCE sNDA with Priority Review and a Jan 28, 2027 target action date.

02

Market read

Traders can update INSM positioning based on raised 2026 revenue guidance and a near-term regulatory catalyst window for ARIKAYCE.

03

What to watch

The guidance raises are tied to commercial momentum and regulatory progress, but investors may still discount for execution risk in Phase 3 TPIP enrollment and future label-expansion outcomes for ARIKAYCE.

Relevance 9/10Novelty 9/10Timing: today’s SEC 8-K with Q3 results and 2026 guidance raises
AlphAI · Earnings readINSM · Third quarter 2026 · ended September 30, 2026

Total Company Revenues of $524.4 Million for the Third Quarter of 2026; BRINSUPRI revenues of $400.1 Million and ARIKAYCE revenues of $124.4 Million.

✓Strong quarter

Total revenues increased 268% to $524.4 million, led by BRINSUPRI revenue of $400.1 million and 29% sequential BRINSUPRI growth. ARIKAYCE revenue increased 9%, the net loss narrowed to $100.3 million from $370.0 million, and the Company raised the low end of 2026 revenue guidance for both commercial products.

Revenue
$524M
268% y/y
ARIKAYCE U.S.
$75.5M
2% y/y
EPS · GAAP
$ (0.46 )

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Product revenues, net, three months ended September 30GAAP$524.4M–268%
Product revenues, net, nine months ended September 30GAAP$1.26B–267%
ARIKAYCE total revenue, three months ended September 30GAAP$124.4M–9%
ARIKAYCE total revenue, nine months ended September 30GAAP$338.8M–8%
ARIKAYCE U.S. revenue, three months ended September 30GAAP$75.5M–2%
ARIKAYCE international revenue, three months ended September 30GAAP$48.9M–21%
ARIKAYCE U.S. revenue, nine months ended September 30GAAP$208.6M–1%
ARIKAYCE international revenue, nine months ended September 30GAAP$130.2M–21%
BRINSUPRI total revenue, three months ended September 30GAAP$400.1M29%NM
BRINSUPRI total revenue, nine months ended September 30GAAP$917.1M–NM
BRINSUPRI U.S. revenue, three months ended September 30GAAP$398.1M–NM
BRINSUPRI international revenue, three months ended September 30GAAP$2M–N/A
BRINSUPRI U.S. revenue, nine months ended September 30GAAP$913.8M–NM
BRINSUPRI international revenue, nine months ended September 30GAAP$3.3M–N/A
Total U.S. revenues, three months ended September 30GAAP$473.6M–364%
Total international revenues, three months ended September 30GAAP$50.8M–26%
Total U.S. revenues, nine months ended September 30GAAP$1.12B–378%
Total international revenues, nine months ended September 30GAAP$133.5M–24%
Cost of product revenues (excluding amortization of intangible assets), three months ended September 30GAAP$78.22M––
Cost of product revenues (excluding amortization of intangible assets), nine months ended September 30GAAP$192.8M––
Research and development, three months ended September 30GAAP$270.0M––
Research and development, nine months ended September 30GAAP$689.5M––
Selling, general and administrative, three months ended September 30GAAP$253.0M––
Selling, general and administrative, nine months ended September 30GAAP$747.8M––
Amortization of intangible assets, three months ended September 30GAAP$5.05M––
Amortization of intangible assets, nine months ended September 30GAAP$9.21M––
Change in fair value of contingent consideration liabilities, three months ended September 30GAAP$7.54M––
Change in fair value of contingent consideration liabilities, nine months ended September 30GAAP−$139.2M––
Total operating expenses, three months ended September 30GAAP$613.8M––
Total operating expenses, nine months ended September 30GAAP$1.50B––
Operating loss, three months ended September 30GAAP−$89.37M––
Operating loss, nine months ended September 30GAAP−$244.2M––
Investment income, three months ended September 30GAAP$11.07M––
Interest expense, three months ended September 30GAAP−$20.41M––
Loss before income taxes, three months ended September 30GAAP−$97.65M––
Provision for income taxes, three months ended September 30GAAP$2.67M––
Net loss, three months ended September 30GAAP−$100.3M––
Net loss, nine months ended September 30GAAP−$277.1M––
Basic and diluted net loss per share, three months ended September 30GAAP$ (0.46 )––
Basic and diluted net loss per share, nine months ended September 30GAAP$ (1.28 )––
Weighted average basic and diluted common shares outstanding, three months ended September 30GAAP218,788––
Weighted average basic and diluted common shares outstanding, nine months ended September 30GAAP217,215––

Segments

SegmentRevenueq/qy/y
ARIKAYCE U.S.ARIKAYCE global revenue grew 9% in the third quarter of 2026 compared to the third quarter of 2025, primarily driven by strong growth in international markets.$75.5M–2%
ARIKAYCE InternationalARIKAYCE global revenue grew 9% in the third quarter of 2026 compared to the third quarter of 2025, primarily driven by strong growth in international markets.$48.9M–21%
ARIKAYCE TotalPrimarily driven by strong growth in international markets.$124.4M–9%
BRINSUPRI U.S.BRINSUPRI global revenue grew 29% in the third quarter of 2026 compared to the second quarter of 2026, driven by strong growth in the U.S. market.$398.1M–NM
BRINSUPRI InternationalBRINSUPRI global revenue grew 29% in the third quarter of 2026 compared to the second quarter of 2026, driven by strong growth in the U.S. market.$2M–N/A
BRINSUPRI TotalDriven by strong growth in the U.S. market.$400.1M29%NM

Full-year 2026 outlook

  • NoteBRINSUPRI revenue guidance: $1.35 billion to $1.4 billion
  • NoteARIKAYCE revenue guidance: $460 million to $470 million
  • NotePeak revenues for BRINSUPRI: more than $7 billion
  • NotePeak revenues for TPIP: more than $6 billion
  • NotePeak revenues for ARIKAYCE: more than $1 billion
  • NoteSubmitting an average of one to two INDs per year from its pre-clinical research programs
  • NoteThe totality of its pre-clinical research programs will comprise less than 20% of overall expenditures

What drove it

  • BRINSUPRI global revenue grew 29% in the third quarter of 2026 compared to the second quarter of 2026, driven by strong growth in the U.S. market.
  • ARIKAYCE global revenue grew 9% in the third quarter of 2026 compared to the third quarter of 2025, primarily driven by strong growth in international markets.
  • Cost of product revenues as a percentage of revenues decreased in the third quarter of 2026 due to sales of BRINSUPRI, which has lower manufacturing costs than ARIKAYCE.
  • R&D expense increased due to manufacturing costs, clinical development and research costs primarily related to TPIP, and compensation, benefits, and stock-based compensation costs primarily related to higher headcount.
  • SG&A expense increased primarily due to professional fees, other external expenses, and compensation and benefit-related expenses driven by BRINSUPRI commercial activities.
  • Japan's MHLW approved BRINSUPRI Tablets 25 mg in August 2026, and Insmed launched the product in Japan in October 2026.
  • The FDA accepted the ARIKAYCE sNDA for MAC lung disease, granted Priority Review, and set a January 28, 2027 PDUFA target action date.

Concerns

  • The Company reported a net loss of $100.3 million for the third quarter of 2026 and a net loss of $277.1 million for the nine months ended September 30, 2026.
  • R&D expenses were $270.0 million and SG&A expenses were $253.0 million for the third quarter of 2026 as the Company funds TPIP development and BRINSUPRI commercialization.
  • ARIKAYCE U.S. revenue was $75.5 million, up 2% from the third quarter of 2025, while international revenue was $48.9 million, up 21%.
  • ARIKAYCE remains subject to an FDA accelerated approval indication in the United States, and the Company is seeking full approval and an expanded label.
  • The Company disclosed $544,862 of long-term debt and $146,231 of royalty financing agreement liabilities as of September 30, 2026.

What to watch

  • BRINSUPRI commercial execution in the U.S. and Japan following the Japan launch in October 2026.
  • FDA action on the ARIKAYCE sNDA for MAC lung disease by the January 28, 2027 PDUFA target action date.
  • Planned fourth-quarter 2026 submission of Phase 3 ENCORE data to Japan's PMDA to support a potential ARIKAYCE label expansion.
  • PALM-ILD enrollment progress, which exceeded 35% of patients, and the expectation to complete enrollment in the first half of 2028.
  • Initiation of the Phase 3 TPIP study in IPF anticipated in the first half of 2027.
  • Progression of INS1033, INS1148, INS1201, and INS1202 clinical programs.

Balance sheet and cash flow

  • Cash and cash equivalents as of September 30, 2026: $ 396,563
  • Marketable securities as of September 30, 2026: $ 750,063
  • Cash, cash equivalents, and marketable securities totaling approximately $1.1 billion as of September 30, 2026.
  • Accounts receivable as of September 30, 2026: $ 259,270
  • Inventory as of September 30, 2026: $ 163,946
  • Total assets as of September 30, 2026: $ 2,226,056
  • Debt, long-term as of September 30, 2026: $ 544,862
  • Current portion of royalty financing agreement as of September 30, 2026: $ 10,232
  • Royalty financing agreement as of September 30, 2026: $ 146,231
  • Total liabilities as of September 30, 2026: $ 1,499,842
  • Total shareholders' equity as of September 30, 2026: $ 726,214

Analysis

Insmed reported a sharp revenue step-up in the third quarter, with product revenues, net of $524.4 million versus $142.3 million in the third quarter of 2025. BRINSUPRI was the principal driver, generating $400.1 million of revenue, including $398.1 million in the U.S. The Company said global BRINSUPRI revenue grew 29% from the second quarter of 2026, driven by strong growth in the U.S. market. ARIKAYCE added $124.4 million of revenue, up 9% from the third quarter of 2025, with international revenue up 21% to $48.9 million and U.S. revenue up 2% to $75.5 million.

The revenue mix supported a substantial improvement in the operating result. Cost of product revenues excluding amortization of intangible assets was $78.2 million, and the Company said cost of product revenues as a percentage of revenues decreased because BRINSUPRI has lower manufacturing costs than ARIKAYCE. Operating loss narrowed to $89.4 million from $366.0 million, while net loss narrowed to $100.3 million, or $0.46 per share, from $370.0 million, or $1.75 per share.

Investment continues to rise alongside commercial expansion and pipeline development. R&D expense was $270.0 million, compared with $186.4 million, reflecting manufacturing costs, clinical development and research costs primarily related to TPIP, and higher headcount-related costs. SG&A expense was $253.0 million, compared with $186.4 million, primarily reflecting professional fees, external expenses, and personnel costs tied to BRINSUPRI commercial activities. The Company held approximately $1.1 billion in cash, cash equivalents, and marketable securities as of September 30, 2026, while long-term debt was $544.9 million.

Management raised the low end of 2026 guidance for both commercial products. BRINSUPRI guidance is now $1.35 billion to $1.4 billion, from $1.25 billion to $1.4 billion, and ARIKAYCE guidance is now $460 million to $470 million, from $450 million to $470 million. The release also advances the commercial and regulatory agenda: BRINSUPRI launched in Japan in October 2026 after MHLW approval, while the FDA accepted the ARIKAYCE sNDA, granted Priority Review, and set a January 28, 2027 target action date.

Pipeline activity remains broad and spending-intensive. PALM-ILD enrollment exceeded 35%, with completion anticipated in the first half of 2028; PALM-PAH enrolled its first patient in July 2026; and PALM-PPF began in September 2026. Insmed continues to anticipate starting an IPF Phase 3 TPIP study in the first half of 2027. The key operating focus is whether BRINSUPRI growth, ARIKAYCE label expansion, and international commercialization continue to support the raised product revenue ranges while the Company funds multiple late-stage and early-stage programs.

Management, verbatim

The third quarter marked another period of meaningful progress, defined by commercial momentum, regulatory achievements, and advancement across our diversified pipeline.

Will Lewis, Chair and Chief Executive Officer

BRINSUPRI’s U.S. launch continues to exceed expectations and ARIKAYCE continues to grow while in its ninth year on the market. This performance supports our decision to raise the low end of our full-year 2026 revenue guidance for both products.

Will Lewis, Chair and Chief Executive Officer

Not in the filing

stated, not guessed
  • Gross margin
  • Operating margin
  • Net loss margin
  • Non-GAAP revenue, earnings, operating income, net income, or EPS
  • Operating cash flow
  • Capital expenditures
  • Free cash flow
  • Share repurchases
  • Dividends
  • Quarterly revenue guidance
  • Full-year total company revenue guidance
  • Gross-margin guidance
  • Operating-expense guidance
  • Tax-rate guidance
  • Prior-quarter values for the consolidated statement of net loss line items
  • A separately provided previous outlook section for formal actual-versus-prior-guidance comparisons

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Insmed’s Q3 2026 update covers commercial performance for BRINSUPRI and ARIKAYCE, plus regulatory and Phase 3 progress across its respiratory pipeline.

Company-level read

Ticker impact

$INSMBullishHigh confidence
Context

Insmed reported Q3 2026 results and raised 2026 BRINSUPRI guidance to $1.35B-$1.4B and ARIKAYCE guidance to $460M-$470M.

Expected impact

Likely upward bias as the market reprices 2026 revenue trajectory and the probability-weighted path to ARIKAYCE label expansion.

Evidence & confidence

The filing includes explicit guidance raises for both commercial products and a concrete regulatory milestone (FDA accepted sNDA with Priority Review and a Jan 28, 2027 PDUFA target), alongside a Japan launch approval and launch timing.

Market effects

Reinforces demand momentum in respiratory specialty biopharma and may lift sentiment for CF/bronchiectasis and MAC-related commercial franchises.

Japan approval and launch expands geographic revenue opportunity and can improve regional growth expectations.

FDA Priority Review and a defined PDUFA target date can affect global comps and risk appetite for respiratory drug developers.

Counterpoint

Revenue growth is strong but the filing also shows much higher R&D and SG&A spend, so margin and cash-flow trajectory may not improve as quickly as top-line guidance.

Key entities

  • Insmed Incorporated

    Nasdaq-listed biopharmaceutical company reporting Q3 2026 results, guidance raises, and regulatory milestones.

  • BRINSUPRI (brensocatib)

    Commercial respiratory therapy; Japan approval and launch plus U.S. growth cited.

  • ARIKAYCE (amikacin liposome inhalation suspension)

    Commercial respiratory therapy; FDA accepted ARIKAYCE sNDA for MAC lung disease with Priority Review.

  • FDA

    Accepted Insmed’s ARIKAYCE sNDA and granted Priority Review with a Jan 28, 2027 target action date.

  • Japan MHLW

    Approved BRINSUPRI tablets 25 mg for non-cystic fibrosis bronchiectasis in Japan.

Every INSM earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$INSMHighAI 8/10

Why Did Insmed Stock Jump?

Insmed (INSM) shares rose 15.1% on October 29, 2026, after reporting Q3 2026 results. Revenue of $524.4M beat estimates, but loss per share was wider. BRINSUPRI revenue grew 29% QoQ, and guidance was raised. R&D and sales costs increased 40% YoY. The stock is down 32.5% over the past year.

$INSMHighAI 9/10

Goldman Sachs reiterates Insmed stock rating on Brinsupri beat

Goldman Sachs maintained a Buy rating and $194 price target for Insmed (INSM) after its quarterly results beat estimates. Brinsupri revenue was $400.1M, exceeding expectations. Insmed raised its 2026 guidance for Brinsupri to $1.35B-$1.40B. The stock rose 19.5% to $111.59. Analysts have revised earnings upwards, with price targets ranging from $165 to $243.

$INSMMed

Insmed Inc (INSM) Q3 2026 Earnings Call Highlights: Brinsupri Hits Blockbuster Status

Insmed Inc (INSM) reported positive Q3 2026 earnings, with Brinsupri showing strong persistency and revenue trends. The company expects cash flow positivity in 2027 and provided updates on TPIP trials and Erakase's label expansion. Dr. Martina Flammer highlighted growth opportunities in comorbid COPD and asthma bronchiectasis, with data expected in mid-2027. Insmed also discussed AI use for patient identification and the potential impact of real-world studies.

$INSMMedAI 8/10

What Insmed (INSM) Said on Its Q3 Earnings Call

Insmed (INSM) reported Q3 earnings, highlighting AI diagnostic tools for bronchiectasis, expected to share findings in 2027. FDA granted priority review for ARIKAYCE's sNDA, with a target action date of Jan. 28, 2027. The company expects cash-flow positivity in 2027. Insmed also provided updates on its pipeline, including TPIP and INS1033 programs. Cost of product revenues was $78.2 million, or 14.9% of revenue, with combined R&D and SG&A expenses up 40% year over year.

$INSMHighAI 8/10

Insmed (INSM) Q3 2026 Earnings Call Transcript

Insmed (INSM) reported Q3 2026 revenue of $400.1M for BRINSUPRI, up 29% sequentially. The company raised its 2026 revenue guidance to $1.35B-$1.4B. Insmed expects its lead respiratory assets to exceed $14B in peak sales, with BRINSUPRI potentially reaching $7B+ and TPIP $6B+.